Printer Friendly

Deal snapshot: ACERUS TO ACQUIRE CANADA RIGHTS TO MEDINOVA'S ESTROGEN/LACTOBACILLUS COMBO GYNOFLOR.

MANews-(C)2009-2016

Canadian drugmaker Acerus Pharmaceuticals Corp. (TSX: ASP) has entered into a license and supply agreement with Swiss pharmaceutical company Medinova AG granting Acerus the exclusive rights to commercialise Gynoflor in Canada, the company said.

Gynoflor is an ultra-low dose estrogen (estriol) and lactobacillus combination vaginal tablet used for the treatment of atrophic vaginitis due to estrogen deficiency during menopause, for the restoration of vaginal flora following the use of anti-infectives and for the treatment of certain vaginal infections.

Country: Switzerland

Sector: Pharmaceuticals

Target: Canadian rights to Gynoflor

Buyer: Acerus Pharmaceuticals

Vendor: Medinova AG

Deal size in USD:

Type: Stakebuilding

Financing: Cash

Status: Agreed

Buyer advisor: , ,

Comment: Terms of the deal were not disclosed

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M & A Navigator
Geographic Code:1CANA
Date:Apr 22, 2016
Words:116
Previous Article:Deal snapshot: ASIAN GROWTH PROPERTIES SELLS CHINA PROPERTY FOR USD 116M.
Next Article:Cryptosoft Buys Identity, Access Management Specialist Device Authority.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |